FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis

Traders Union
All News
Companies
Artiva gains RMAT for AlloNK combo

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Companies

Regulators News

Central Banks News

Ivan Andriyenko

08.06.2026

FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis — Artiva gains RMAT for AlloNK combo

Artiva Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its AlloNK product in combination with rituximab for the treatment of refractory rheumatoid arthritis.

The RMAT designation is intended to expedite the development and regulatory review of promising regenerative medicine therapies that address unmet medical needs. This marks a significant milestone for Artiva Biotherapeutics, Inc. as the company advances its therapeutic pipeline targeting difficult-to-treat autoimmune diseases.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Artiva Biotherapeutics plans a Phase 3 trial of AlloNK targeting deep B-cell depletion in refractory rheumatoid arthritis. CEO Fred Aslan is expected to discuss AlloNK Phase 3 developments at the 2026 Jefferies Healthcare Conference. The company continues to advance its clinical program for difficult-to-treat autoimmune conditions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Toncoin becomes Gram: Why Durov restored token's original name

By Anastasiia Chabaniuk
25 min ago

Toncoin becomes Gram: Why Durov restored token's original name

Editors' Picks

Why Tether flipping Ethereum is a pivotal moment for crypto

By Kyle Torpey
22 hours ago

Why Tether flipping Ethereum is a pivotal moment for crypto

Editors' Picks

MiCA deadline: Why crypto companies are leaving Europe

By Eugene Komchuk
Yesterday

MiCA deadline: Why crypto companies are leaving Europe

Editors' Picks

All Editors' Top Picks

Latest Artiva News

$Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis$

By Andreas Kristo
04.06.2026

Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis

Companies

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

By Oleg Tkachenko
28.05.2026

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

Companies

Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases

By Ivan Andriyenko
19.05.2026

Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases

Companies

All Artiva News

Anastasiia Chabaniuk
25 min ago

Toncoin becomes Gram: Why Durov restored token's original name

Kyle Torpey
22 hours ago

Why Tether flipping Ethereum is a pivotal moment for crypto

Eugene Komchuk
Yesterday

MiCA deadline: Why crypto companies are leaving Europe

Mikhail Vnuchkov
13.06.2026

From “Holy Trinity” to WLD crash: How Arthur Hayes became a market-moving seller

Eugene Komchuk
12.06.2026

The world's first trillionaire: How Musk built his fortune on electric cars, space and AI

Andreas Kristo
5 min ago

Javier Blas: Murban crude from UAE shifts to contango as time spreads collapse

Elena Nikulina
14 min ago

Record 45% of central bank reserve managers expect to add gold, Peter Spina notes

Daria Chernytska
14 min ago

Justin Sun: Tron Academy expands engagement at ETHGlobal

Yaroslav Dmytrenko
15 min ago

Digital fraud awareness campaign launched in India, Sumit Gupta notes

Hanna Syniavska
45 min ago

Confusion between bitcoin and crypto continues, Christian Keroles notes

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Ivan Andriyenko
29 min ago

U.S. futures steady as markets weigh Iran deal

U.S. futures steady as markets weigh Iran deal

Andrey Mastykin
1 hour ago

Oil slips as U.S.-Iran deal raises hopes for Hormuz reopening

Oil slips as U.S.-Iran deal raises hopes for Hormuz reopening

Eugene Komchuk
2 hours ago

Bitcoin rises to $66,000 after Bank of Japan rate hike

Bitcoin rises to $66,000 after Bank of Japan rate hike

Olga Shendetskaya
17 hours ago

Nvidia returns to bond market as AI borrowing wave grows

Nvidia returns to bond market as AI borrowing wave grows

Parshwa Turakhiya
20 hours ago

ByteDance seeks Chinese AI chips amid U.S. restrictions

ByteDance seeks Chinese AI chips amid U.S. restrictions

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

BT Group stands out as broadband rivals struggle

Mykhailo Ihnatenko
Now

Solana rebounds as markets await Fed decision

Anton Kharitonov
Now

Google gains as easing Middle East tensions support market sentiment

Anton Kharitonov
Now

Microsoft attempts to build base as risk appetite returns

Mykhailo Ihnatenko
Now

Tesla rebounds as SpaceX draws attention away from stock

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.